Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 32, Issue 8
  5. Article
Volume 32, Issue 8
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Colorectal cancer (CRC) is a significant health issue, with countless individuals suffering. With its bleak outlook, the number of deaths caused by CRC can only be reduced if new diagnostic and prognostic biomarkers are identified and developed quickly. Recent developments in screening programme development and patient management have been encouraging, but many unanswered questions still need to be addressed before a customized colorectal cancer approach can be implemented. Prevention of diseases, the detection of them in their early stages, the analysis of the severity, and the treatment of any metastasized diseases are all paramount. Despite the increased utilization of genetic profiles in decision-making processes, such as the selection of therapy and predicting drug response, there are only a limited number of validated biomarkers for colorectal cancer that are suitable for clinical practice. To further research into colorectal carcinogenesis, pinpoint prospective indicators, and validate these indicators, creating non-intrusive, sensitive, and exact biomarkers is an urgent requirement. This procedure is reliant on translational proteomics. This investigation serves as a comprehensive resource on the current state of genetic and epigenetic biomarkers in diagnosing, predicting, and evaluating colorectal cancer. It underscores the transformative potential of these biomarkers in advancing CRC patient care, from early detection to personalized treatment strategies. However, it also underscores the need for ongoing research and validation to realize their clinical utility fully.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673274455231219044728
2024-01-31
2025-06-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673274455231219044728
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GhasemzadehN. ZafariA.M. A brief journey into the history of the arterial pulse.Cardiol. Res. Pract.2011201116483210.4061/2011/164832
     [Google Scholar]
  2. HosseiniE.S. MohammadiS. KhodarahmiR. FouaniM.H. TavallaeiO. JaberiK.R. ShabaninejadZ. JanfazaS. Yazdian-RobatiR. SajadimajdS. New insights into the biosensing of parkinson’s disease biomarkers: A concise review.Curr. Med. Chem.202229223945397210.2174/092986732866621121311181234961452
     [Google Scholar]
  3. BedinC. CrottiS. TasciottiE. AgostiniM. Diagnostic devices for circulating biomarkers detection and quantification.Curr. Med. Chem.201825344304432710.2174/092986732466617111612425529149830
     [Google Scholar]
  4. ColburnW. DeGruttolaV.G. DeMetsD.L. DowningG.J. HothD.F. OatesJ.A. PeckC.C. SchooleyR.T. SpilkerB.A. WoodcockJ. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.Clin. Pharmacol. Ther.2001693899510.1067/mcp.2001.11398911240971
     [Google Scholar]
  5. OngF.S. DasK. WangJ. VakilH. KuoJ.Z. BlackwellW.L.B. LimS.W. GoodarziM.O. BernsteinK.E. RotterJ.I. GrodyW.W. Personalized medicine and pharmacogenetic biomarkers: Progress in molecular oncology testing.Expert Rev. Mol. Diagn.201212659360210.1586/erm.12.5922845480
     [Google Scholar]
  6. MertD.G. TerziH. Mean platelet volume in bipolar disorder: The search for an ideal biomarker.Neuropsychiatr. Dis. Treat.2016122057206210.2147/NDT.S11237427578978
     [Google Scholar]
  7. ArnoldM. SierraM.S. LaversanneM. SoerjomataramI. JemalA. BrayF. Global patterns and trends in colorectal cancer incidence and mortality.Gut201766468369110.1136/gutjnl‑2015‑31091226818619
     [Google Scholar]
  8. LichtensternC.R. NguR.K. ShalapourS. KarinM. Immunotherapy, inflammation and colorectal cancer.Cells20209361810.3390/cells903061832143413
     [Google Scholar]
  9. GuttR. DawsonG. CheukA.V. FosmireH. MoghanakiD. KellyM. JollyS. Palliative radiotherapy for the management of metastatic cancer: Bone metastases, spinal cord compression, and brain metastases.Fed. Pract.20153212S16S30766118
     [Google Scholar]
  10. MarventanoS. ForjazM.J. GrossoG. MistrettaA. GiorgianniG. PlataniaA. GangiS. BasileF. BiondiA. Health related quality of life in colorectal cancer patients: State of the art.BMC Surg.20131321510.1186/1471‑2482‑13‑S2‑S1524267735
     [Google Scholar]
  11. DeschoolmeesterV. BaayM. SpecenierP. LardonF. VermorkenJ.B. A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy.Oncologist201015769973110.1634/theoncologist.2010‑002520584808
     [Google Scholar]
  12. CarethersJ.M. JungB.H. Genetics and genetic biomarkers in sporadic colorectal cancer.Gastroenterology2015149511771190.e310.1053/j.gastro.2015.06.04726216840
     [Google Scholar]
  13. LiuD. Cancer biomarkers for targeted therapy.Biomark. Res.2019712510.1186/s40364‑019‑0178‑731807308
     [Google Scholar]
  14. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Available from:https://www.medscape.org/viewarticle/578950 (Accessed on 25 July 2023)
  15. SellS. Alpha-fetoprotein, stem cells and cancer: How study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer.Tumour Biol.200829316118010.1159/00014340218612221
     [Google Scholar]
  16. Zi-yangY. KaixunZ. DonglingL. ZhouY. ChengbinZ. JimeiC. CaojinZ. Carcinoembryonic antigen levels are increased with pulmonary output in pulmonary hypertension due to congenital heart disease.J. Int. Med. Res.2020481130006052096437810.1177/030006052096437833203284
     [Google Scholar]
  17. GoslinR. O’BrienM.J. SteeleG. MayerR. WilsonR. CorsonJ.M. ZamcheckN. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer.Am. J. Med.198171224625310.1016/0002‑9343(81)90125‑X6167166
     [Google Scholar]
  18. MesriM. Advances in proteomic technologies and its contribution to the field of cancer.Adv. Med.2014201412510.1155/2014/23804526556407
     [Google Scholar]
  19. HenryN.L. HayesD.F. Cancer biomarkers.Mol. Oncol.20126214014610.1016/j.molonc.2012.01.01022356776
     [Google Scholar]
  20. SarhadiV.K. ArmengolG. Molecular biomarkers in cancer.Biomolecules2022128102110.3390/biom1208102135892331
     [Google Scholar]
  21. SrivastavaS. Cancer biomarker discovery and development in gastrointestinal cancers: Early detection research network-a collaborative approach.Gastrointest. Cancer Res.200714S60S6319360150
     [Google Scholar]
  22. GoossensN. NakagawaS. SunX. HoshidaY. Cancer biomarker discovery and validation.Transl. Cancer Res.20154325626926213686
     [Google Scholar]
  23. SarathS. JosephD.H.V.T. FarhadulI. VinodG. Protein cancer biomarkers, current.Cancer Biomark.2023132148179Available from: https://www.eurekaselect.com/ chapter/18578
    [Google Scholar]
  24. PepeM.S. EtzioniR. FengZ. PotterJ.D. ThompsonM.L. ThornquistM. WingetM. YasuiY. Phases of biomarker development for early detection of cancer.J. Natl. Cancer Inst.200193141054106110.1093/jnci/93.14.105411459866
     [Google Scholar]
  25. SauerJ.M. PorterA.C. Preclinical biomarker qualification.Exp. Biol. Med.2018243322222710.1177/153537021774394929171289
     [Google Scholar]
  26. LeeJ.W. FigeysD. VasilescuJ. Biomarker assay translation from discovery to clinical studies in cancer drug development: Quantification of emerging protein biomarkers.Adv. Cancer Res.20069626929810.1016/S0065‑230X(06)96010‑217161683
     [Google Scholar]
  27. ChenG. HuangS. WengW. SuC. Statistical Methods in Biomarker and Early Clinical Development. FangL. SuC. ChamSpringer International Publishing20198711510.1007/978‑3‑030‑31503‑0_6
     [Google Scholar]
  28. WagnerP.D. SrivastavaS. New paradigms in translational science research in cancer biomarkers.Transl. Res.2012159434335310.1016/j.trsl.2012.01.01522424436
     [Google Scholar]
  29. PolleyM.C. KornE.L. FreidlinB. Phase III precision medicine clinical trial designs that integrate treatment and biomarker evaluation.JCO Precis. Oncol.201931910.1200/PO.18.0041632923845
     [Google Scholar]
  30. PeschB. BrüningT. JohnenG. CasjensS. BonbergN. TaegerD. MüllerA. WeberD.G. BehrensT. Biomarker research with prospective study designs for the early detection of cancer.Biochim. Biophys. Acta. Proteins Proteomics20141844587488310.1016/j.bbapap.2013.12.00724361552
     [Google Scholar]
  31. OuF.S. MichielsS. ShyrY. AdjeiA.A. ObergA.L. Biomarker discovery and validation: Statistical considerations.J. Thorac. Oncol.202116453754510.1016/j.jtho.2021.01.161633545385
     [Google Scholar]
  32. FreidlinB. McShaneL.M. KornE.L. Randomized clinical trials with biomarkers: Design issues.J. Natl. Cancer Inst.2010102315216010.1093/jnci/djp47720075367
     [Google Scholar]
  33. CagneyD.N. SulJ. HuangR.Y. LigonK.L. WenP.Y. AlexanderB.M. The FDA NIH biomarkers, endpoints, and other tools (BEST) resource in neuro-oncology.Neuro-oncol.20182091162117210.1093/neuonc/nox24229294069
     [Google Scholar]
  34. CaliffR.M. Biomarker definitions and their applications.Exp. Biol. Med.2018243321322110.1177/153537021775008829405771
     [Google Scholar]
  35. HussR. Translational Regenerative Medicine. AtalaA. AllicksonJ.G. BostonAcademic Press201523524110.1016/B978‑0‑12‑410396‑2.00019‑0
     [Google Scholar]
  36. ForeroD.A. ChandV. Methods in molecular biology and genetics: Looking to the future.BMC Res. Notes20231612610.1186/s13104‑023‑06298‑y36864454
     [Google Scholar]
  37. BodaghiA. FattahiN. RamazaniA. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.Heliyon202392e1332310.1016/j.heliyon.2023.e1332336744065
     [Google Scholar]
  38. DuffyM.J. Tumor markers in clinical practice: A review focusing on common solid cancers.Med. Princ. Pract.201322141110.1159/00033839322584792
     [Google Scholar]
  39. SharmaS. Tumor markers in clinical practice: General principles and guidelines.Indian J. Med. Paediatr. Oncol.20093011810.4103/0971‑5851.5632820668599
     [Google Scholar]
  40. KalaveS. HegdeN. JuvaleK. Applications of nanotechnology-based approaches to overcome multi-drug resistance in cancer.Curr. Pharm. Des.202228383140315710.2174/138161282866622040114230035366765
     [Google Scholar]
  41. World health organization. Cancer today 2024.Available from: https://gco.iarc.fr/
  42. RawlaP. SunkaraT. BarsoukA. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors.Prz. Gastroenterol.20191428910310.5114/pg.2018.8107231616522
     [Google Scholar]
  43. TariqK. TariqK. GhiasK. GhiasK. Colorectal cancer carcinogenesis: A review of mechanisms.Cancer Biol. Med.201613112013510.20892/j.issn.2095‑3941.2015.010327144067
     [Google Scholar]
  44. DadarM. DhamaK. IqbalH. MunjalA. KhandiaR. KarthikK. SachanS. LatheefS.K. SamadH.A. JoshiS.K. Molecular signatures of biomarkers in cancer development, diagn osis, and its prognostic accuracy.Curr. Bio. Recent Pat. Bio.201662899610.2174/2468422807666170210164253
     [Google Scholar]
  45. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  46. KulasingamV. DiamandisE.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.Nat. Clin. Pract. Oncol.200851058859910.1038/ncponc118718695711
     [Google Scholar]
  47. Alves MartinsB.A. de BulhõesG.F. CavalcantiI.N. MartinsM.M. de OliveiraP.G. MartinsA.M.A. Biomarkers in colorectal cancer: The role of translational proteomics research.Front. Oncol.20199128410.3389/fonc.2019.0128431828035
     [Google Scholar]
  48. AnghelS.A. Ioniță-MîndricanC.B. LucaI. PopA.L. Promising epigenetic biomarkers for the early detection of colorectal cancer: A systematic review.Cancers20211319496510.3390/cancers1319496534638449
     [Google Scholar]
  49. BalchenV. SimonK. Colorectal cancer development and advances in screening.Clin. Interv. Aging20161196797610.2147/CIA.S10928527486317
     [Google Scholar]
  50. SteeleS.R. JohnsonE.K. ChampagneB. DavisB. LeeS. RivadeneiraD. RossH. HaydenD.A. MaykelJ.A. Endoscopy and polyps-diagnostic and therapeutic advances in management.World J. Gastroenterol.201319274277428810.3748/wjg.v19.i27.427723885138
     [Google Scholar]
  51. BieA.K.L. BrodersenJ. Why do some participants in colorectal cancer screening choose not to undergo colonoscopy following a positive test result? A qualitative study.Scand. J. Prim. Health Care201836326227110.1080/02813432.2018.148752030238859
     [Google Scholar]
  52. GhazanfarS. FatimaI. AslamM. MusharrafS.G. ShermanN.E. MoskalukC. FoxJ.W. AkhtarM.W. SadafS. Identification of actin beta-like 2 (ACTBL2) as novel, upregulated protein in colorectal cancer.J. Proteomics2017152334010.1016/j.jprot.2016.10.01127989943
     [Google Scholar]
  53. HaoJ.J. ZhiX. WangY. ZhangZ. HaoZ. YeR. TangZ. QianF. WangQ. ZhuJ. Comprehensive proteomic characterization of the human colorectal carcinoma reveals signature proteins and perturbed pathways.Sci. Rep.2017714243610.1038/srep4243628181595
     [Google Scholar]
  54. Quesada-CalvoF. MassotC. BertrandV. LonguespéeR. BlétardN. SomjaJ. MazzucchelliG. SmargiassoN. BaiwirD. De Pauw-GilletM.C. DelvenneP. MalaiseM. Coimbra MarquesC. PolusM. De PauwE. MeuwisM.A. LouisE. OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages.Clin. Proteomics2017141910.1186/s12014‑017‑9143‑328344541
     [Google Scholar]
  55. YamamotoT. KudoM. PengW.X. TakataH. TakakuraH. TedukaK. FujiiT. MitamuraK. TagaA. UchidaE. NaitoZ. Identification of aldolase A as a potential diagnostic biomarker for colorectal cancer based on proteomic analysis using formalin-fixed paraffin-embedded tissue.Tumour Biol.20163710135951360610.1007/s13277‑016‑5275‑827468721
     [Google Scholar]
  56. TowlerB. IrwigL. GlasziouP. KewenterJ. WellerD. SilagyC. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult.BMJ1998317715855956510.1136/bmj.317.7158.5599721111
     [Google Scholar]
  57. KronborgO. FengerC. OlsenJ. JørgensenO.D. SøndergaardO. Randomised study of screening for colorectal cancer with faecal-occult-blood test.Lancet199634890401467147110.1016/S0140‑6736(96)03430‑78942774
     [Google Scholar]
  58. FerrariA. NeefsI. HoeckS. PeetersM. Van HalG. Towards novel non-invasive colorectal cancer screening methods: A comprehensive review.Cancers2021138182010.3390/cancers1308182033920293
     [Google Scholar]
  59. DingQ. KongX. ZhongW. LiuW. Fecal biomarkers: Non-invasive diagnosis of colorectal cancer.Front. Oncol.20221297193010.3389/fonc.2022.97193036119474
     [Google Scholar]
  60. MokhtariR.B. HomayouniT.S. BaluchN. MorgatskayaE. KumarS. DasB. YegerH. Combination therapy in combating cancer.Oncotarget2017823380223804310.18632/oncotarget.1672328410237
     [Google Scholar]
  61. VannemanM. DranoffG. Combining immunotherapy and targeted therapies in cancer treatment.Nat. Rev. Cancer201212423725110.1038/nrc323722437869
     [Google Scholar]
  62. KrzyszczykP. AcevedoA. DavidoffE.J. TimminsL.M. Marrero-BerriosI. PatelM. WhiteC. LoweC. SherbaJ.J. HartmanshennC. O’NeillK.M. BalterM.L. FritzZ.R. AndroulakisI.P. SchlossR.S. YarmushM.L. The growing role of precision and personalized medicine for cancer treatment.Technology2018603n047910010.1142/S233954781830002030713991
     [Google Scholar]
  63. GuoJ. ZhuC. YangK. LiJ. DuN. ZongM. ZhouJ. HeJ. Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer.Oncotarget201788133121331910.18632/oncotarget.1451628076324
     [Google Scholar]
  64. MartinP. NoonanS. MullenM.P. ScaifeC. TosettoM. NolanB. WynneK. HylandJ. SheahanK. EliaG. O’DonoghueD. FennellyD. O’SullivanJ. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.BMC Cancer201414188710.1186/1471‑2407‑14‑88725428203
     [Google Scholar]
  65. BallmanK.V. Biomarker: Predictive or prognostic?J. Clin. Oncol.201533333968397110.1200/JCO.2015.63.365126392104
     [Google Scholar]
  66. ParmarS. EaswaranH. Genetic and epigenetic dependencies in colorectal cancer development.Gastroenterol. Rep.202210goac03510.1093/gastro/goac03535975243
     [Google Scholar]
  67. SchwarzenbachH. HoonD.S.B. PantelK. Cell-free nucleic acids as biomarkers in cancer patients.Nat. Rev. Cancer201111642643710.1038/nrc306621562580
     [Google Scholar]
  68. GilliesR.J. KinahanP.E. HricakH. Radiomics: Images are more than pictures, they are data.Radiology2016278256357710.1148/radiol.201515116926579733
     [Google Scholar]
  69. PalM. MuinaoT. BoruahH.P.D. MahindrooN. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges.Biomed. Pharmacother.202214611248810.1016/j.biopha.2021.11248834894516
     [Google Scholar]
  70. DengK. YangL. HuB. WuH. ZhuH. TangC. The prognostic significance of pretreatment serum CEA levels in gastric cancer: A meta-analysis including 14651 patients.PLoS One2015104e012415110.1371/journal.pone.012415125879931
     [Google Scholar]
  71. LitvakA. CercekA. SegalN. Reidy-LagunesD. StadlerZ.K. YaegerR.D. KemenyN.E. WeiserM.R. PessinM.S. SaltzL. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.J. Natl. Compr. Canc. Netw.201412690791310.6004/jnccn.2014.008524925201
     [Google Scholar]
  72. ZhuD. ZhongY. WuH. YeL. WangJ. LiY. WeiY. RenL. XuB. XuJ. Predicting metachronous liver metastasis from colorectal cancer using serum proteomic fingerprinting.J. Surg. Res.2013184286186610.1016/j.jss.2013.04.06523721930
     [Google Scholar]
  73. FarrellP.M. RosensteinB.J. WhiteT.B. AccursoF.J. CastellaniC. CuttingG.R. DurieP.R. LeGrysV.A. MassieJ. ParadR.B. RockM.J. CampbellP.W.III Cystic Fibrosis Foundation Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.J. Pediatr.20081532S4S1410.1016/j.jpeds.2008.05.00518639722
     [Google Scholar]
  74. KyleR.A. TherneauT.M. RajkumarS.V. OffordJ.R. LarsonD.R. PlevakM.F. MeltonL.J.III A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N. Engl. J. Med.2002346856456910.1056/NEJMoa0113320211856795
     [Google Scholar]
  75. TanD.S.P. IravaniM. McCluggageW.G. LambrosM.B.K. MilaneziF. MackayA. GourleyC. GeyerF.C. VatchevaR. MillarJ. ThomasK. NatrajanR. SavageK. FenwickK. WilliamsA. JamesonC. El-BahrawyM. GoreM.E. GabraH. KayeS.B. AshworthA. Reis-FilhoJ.S. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.Clin. Cancer Res.20111761521153410.1158/1078‑0432.CCR‑10‑168821411445
     [Google Scholar]
  76. BasuN.N. InghamS. HodsonJ. LallooF. BulmanM. HowellA. EvansD.G. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A 30-year semi-prospective analysis.Fam. Cancer201514453153810.1007/s10689‑015‑9825‑926239694
     [Google Scholar]
  77. WasungM.E. ChawlaL.S. MaderoM. Biomarkers of renal function, which and when?Clin. Chim. Acta201543835035710.1016/j.cca.2014.08.03925195004
     [Google Scholar]
  78. Chartier-HarilnM.C. ParfittM. LegrainS. Pérez-TurJ. BrousseauT. EvansA. BerrC. VldalO. RoquesP. GourletV. FruchartJ.C. DelacourteA. RossorM. AmouyelP. Apolipoprotein E, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: Analysis of the 19q13.2 chromosomal region.Hum. Mol. Genet.19943456957410.1093/hmg/3.4.5698069300
     [Google Scholar]
  79. PET/MRI of Primary Sclerosing Cholangitis. Available from: https://classic.clinicaltrials.gov/ct2/show/ (Accessed on 30 June 2023.)
  80. MenetskiJ.P. HoffmannS.C. CushS.S. KamphausT.N. AustinC.P. HerrlingP.L. WagnerJ.A. The FNIH Biomarkers Consortium The foundation for the national institutes of health biomarkers consortium: Past accomplishments and new strategic direction.Clin. Pharmacol. Ther.2019105482984310.1002/cpt.136230648736
     [Google Scholar]
  81. DrabovichA.P. PavlouM.P. BatruchI. DiamandisE.P. In proteomic and metabolomic approaches to biomarker discovery. IssaqH.J. VeenstraT.D. Academic PressBoston20131737
     [Google Scholar]
  82. ZhengY. Study design considerations for cancer biomarker discoveries.J. Appl. Lab. Med.20183228228910.1373/jalm.2017.02580930828695
     [Google Scholar]
  83. DavisK.D. AghaeepourN. AhnA.H. AngstM.S. BorsookD. BrentonA. BurczynskiM.E. CreanC. EdwardsR. GaudilliereB. HergenroederG.W. IadarolaM.J. IyengarS. JiangY. KongJ.T. MackeyS. SaabC.Y. SangC.N. ScholzJ. SegerdahlM. TraceyI. VeasleyC. WangJ. WagerT.D. WasanA.D. PelleymounterM.A. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: Challenges and opportunities.Nat. Rev. Neurol.202016738140010.1038/s41582‑020‑0362‑232541893
     [Google Scholar]
  84. HunterD.J. LosinaE. GuermaziA. BursteinD. LassereM.N. KrausV. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Curr. Drug Targets201011553654510.2174/13894501079101194720199395
     [Google Scholar]
  85. SongJ.W. ChungK.C. Observational studies: Cohort and case-control studies.Plast. Reconstr. Surg.201012662234224210.1097/PRS.0b013e3181f44abc20697313
     [Google Scholar]
  86. ChauC.H. RixeO. McLeodH. FiggW.D. Validation of analytic methods for biomarkers used in drug development.Clin. Cancer Res.200814195967597610.1158/1078‑0432.CCR‑07‑453518829475
     [Google Scholar]
  87. WagnerJ.A. Overview of biomarkers and surrogate endpoints in drug development.Dis. Markers2002182414610.1155/2002/92927412364809
     [Google Scholar]
  88. BaiJ.P.F. BellR. BuckmanS. BurckartG.J. EichlerH.G. FangK.C. GoodsaidF.M. JuskoW.J. LeskoL.L. MeibohmB. PattersonS.D. PuigO. SmerageJ.B. SniderB.J. WagnerJ.A. WangJ. WaltonM.K. WeinerR. Translational biomarkers: From preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop.AAPS J.201113227428310.1208/s12248‑011‑9265‑x21448748
     [Google Scholar]
  89. TaubeS.E. ClarkG.M. DanceyJ.E. McShaneL.M. SigmanC.C. GutmanS.I. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.J. Natl. Cancer Inst.2009101211453146310.1093/jnci/djp33419855077
     [Google Scholar]
  90. BaiR. LvZ. XuD. CuiJ. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.Biomark. Res.2020813410.1186/s40364‑020‑00209‑032864131
     [Google Scholar]
  91. VohoraD. SinghG. Pharmaceutical medicine and translational clinical research.Academic Press, 1st Edition2017 https://shop.elsevier.com/books/pharmaceutical-medicine-and-translational-clinical-research/vohora/978-0-12-802103-3
    [Google Scholar]
  92. ICH E15Definitions for genomic biomarkers, pharmacogenimics, pharmacogenetics, genomic data and sample coding categories.Available from: https://database.ich.org/sites/default/files/E15_Guideline.pdf 2023
  93. KabbaniD. AkikaR. WahidA. DalyA.K. CascorbiI. ZgheibN.K. Pharmacogenomics in practice: A review and implementation guide.Front. Pharmacol.202314118997610.3389/fphar.2023.118997637274118
     [Google Scholar]
  94. PhillipsK.A. Van BebberS.L. Measuring the value of pharmacogenomics.Nat. Rev. Drug Discov.20054650050910.1038/nrd174915915153
     [Google Scholar]
  95. McCamishM. IzumiR. Perspectives on development of a combination pharmacogenomic diagnostic and drug product.Pharmacogenomics2006771045104910.2217/14622416.7.7.1045
     [Google Scholar]
  96. Department of health and human services, 2011.Available from: https://www.ema.europa.eu/en/glossary/biomarker
  97. Available from: https://www.ema.europa.eu/en/glossary/biomarker (Accessed on 24 July 2023.)2023
  98. StrattonM.R. CampbellP.J. FutrealP.A. The cancer genome.Nature2009458723971972410.1038/nature0794319360079
     [Google Scholar]
  99. GreavesM. MaleyC.C. Clonal evolution in cancer.Nature2012481738130631310.1038/nature1076222258609
     [Google Scholar]
  100. BergerM.F. MardisE.R. The emerging clinical relevance of genomics in cancer medicine.Nat. Rev. Clin. Oncol.201815635336510.1038/s41571‑018‑0002‑629599476
     [Google Scholar]
  101. GuptaS. VenkateshA. RayS. SrivastavaS. Challenges and prospects for biomarker research: A current perspective from the developing world.Biochim. Biophys. Acta. Proteins Proteomics20141844589990810.1016/j.bbapap.2013.12.02024412545
     [Google Scholar]
  102. RobertC. KaraszewskaB. SchachterJ. RutkowskiP. MackiewiczA. StroiakovskiD. LichinitserM. DummerR. GrangeF. MortierL. Chiarion-SileniV. DrucisK. KrajsovaI. HauschildA. LoriganP. WolterP. LongG.V. FlahertyK. NathanP. RibasA. MartinA.M. SunP. CristW. LegosJ. RubinS.D. LittleS.M. SchadendorfD. Improved overall survival in melanoma with combined dabrafenib and trametinib.N. Engl. J. Med.20153721303910.1056/NEJMoa141269025399551
     [Google Scholar]
  103. MaloneE.R. OlivaM. SabatiniP.J.B. StockleyT.L. SiuL.L. Molecular profiling for precision cancer therapies.Genome Med.2020121810.1186/s13073‑019‑0703‑131937368
     [Google Scholar]
  104. YapT.A. OmlinA. de BonoJ.S. Development of therapeutic combinations targeting major cancer signaling pathways.J. Clin. Oncol.201331121592160510.1200/JCO.2011.37.641823509311
     [Google Scholar]
  105. TsimberidouA.M. FountzilasE. NikanjamM. KurzrockR. Review of precision cancer medicine: Evolution of the treatment paradigm.Cancer Treat. Rev.20208610201910.1016/j.ctrv.2020.10201932251926
     [Google Scholar]
  106. PrasadK. BreckenridgeA. Pharmacogenomics: A new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.Drug Discov. Today20111619-2086787210.1016/j.drudis.2011.08.01621920454
     [Google Scholar]
  107. OverbyC.L. KohaneI. KannryJ.L. WilliamsM.S. StarrenJ. BottingerE. GottesmanO. DennyJ.C. WengC. Tarczy-HornochP. HripcsakG. Opportunities for genomic clinical decision support interventions.Genet. Med.2013151081782310.1038/gim.2013.12824051479
     [Google Scholar]
  108. GoodsaidF. Challenges of biomarkers in drug discovery and development.Expert Opin. Drug Discov.20127645746110.1517/17460441.2012.67961522471322
     [Google Scholar]
  109. OtsuboY. IshiguroA. UyamaY. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.Pharmacogenomics201314219520310.2217/pgs.12.19423327579
     [Google Scholar]
  110. CoppedèF. LopomoA. SpisniR. MiglioreL. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.World J. Gastroenterol.201420494395610.3748/wjg.v20.i4.94324574767
     [Google Scholar]
  111. LoktionovA. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?World J. Gastrointest. Oncol.202012212414810.4251/wjgo.v12.i2.12432104546
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673274455231219044728
Loading
Current Trends in the Biomarker's Discovery for the Treatment and Management of Colorectal Cancer: A Comprehensive Review
Curr. Med. Chem. 32, 1469 (2025); https://doi.org/10.2174/0109298673274455231219044728
/content/journals/cmc/10.2174/0109298673274455231219044728
/content/journals/cmc/10.2174/0109298673274455231219044728
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biochemical response; Biomarkers; colon cancer; diagnostic biomarkers; predictive biomarkers; validation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test